Lupin launches Mirabegron 50 mg US generic in 2024

What Lupin announced

Lupin Limited said it has launched Mirabegron Extended-Release Tablets, 50 mg in the United States after receiving approval from the US Food and Drug Administration (US FDA). The company described the product as a generic equivalent of Myrbetriq Extended-Release Tablets, 50 mg from Astellas Pharma Global Development, Inc. The announcement was dated September 4, 2024, from Mumbai and Naples. The product is used to treat symptoms associated with overactive bladder (OAB), including incontinence, urgency, and frequent urination. The same drug is also used for neurogenic detrusor overactivity (NDO).

Why Mirabegron matters in the US market

Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of USD 1,600 million in the US, based on IQVIA MAT July 2024. Using the rupee value cited alongside the same estimate, that is about Rs 13,437 crore of annual sales in the US market. For Indian investors tracking US generic launches, the size of the reference market is a key data point because it sets the upper bound of the opportunity. Actual generic revenues depend on pricing, competition, and the pace of substitution, among other factors. Lupin’s launch places it directly into a large US prescription segment linked to chronic urology care.

Regulatory approval and launch details

Lupin said the launch followed US FDA approval for the 50 mg extended-release tablets. The company’s communication positioned the product as a direct generic equivalent of Astellas’ Myrbetriq at the same strength. The announcement reiterates that the sales estimate is tied to the US market and uses IQVIA’s moving annual total dataset as of July 2024. The launch is not a future intention but an announced commercial start in the US.

Competitive landscape: approvals and exclusivity window

A key detail highlighted in market commentary is that only Lupin and Zydus have approval for both 25 mg and 50 mg strengths of mirabegron extended-release tablets. That matters because it can help a generic supplier offer a more complete portfolio to pharmacies and payers. The same commentary added that Lupin and Zydus could enjoy a six-month exclusivity period because other players are seen as unlikely to enter before court matters are resolved. This potential exclusivity window, if it holds in practice, can shape early pricing and volumes.

Litigation status and “at-risk” launch

The product “remains in litigation,” and commentary around the launch described it as “at risk.” In US generics, an at-risk launch typically means commercialisation begins while patent litigation is unresolved, which can increase uncertainty around the duration of sales and possible legal outcomes. Lupin’s announcement itself focused on the approval and launch, while external views emphasised the litigation backdrop. Investors generally track these situations closely because legal developments can influence continuity of supply and competitive dynamics.

Stock market reaction on the day

Following reports of the launch and approval, Lupin shares rose 1.46% to Rs 2,271.90. The stock also touched Rs 2,280.95 intraday, described as an all-time high in one market update. A separate market report cited the stock moving to a new 52-week high of Rs 2,284, up over 1.6% on the NSE. These price points were reported in the context of the US launch announcement and the size of the referenced market opportunity.

Lupin’s business context mentioned in reports

Alongside the product update, reports described Lupin as an innovation-led transnational pharmaceutical company with operations across the US, India, South Africa, and other regions including APAC, LATAM, Europe, and the Middle East. One report also cited a quarterly geographic split, stating that 37% came from the US at Rs 2,040 crore, while India reported Rs 1,925 crore for the same quarter. While this split is not presented as being directly driven by mirabegron, it provides context on the importance of the US business to Lupin’s overall performance.

Key facts at a glance

Market impact: what investors are likely tracking

The immediate market impact in the reports was the stock’s move higher on the day, alongside references to new highs. Beyond the one-day price action, the numbers investors may track are the Rs 13,437 crore annual sales estimate for the molecule in the US and the competitive claim that Lupin is among only two players with both key strengths approved. The litigation note is another factor because it can affect the visibility of revenues and the stability of the competitive landscape. Finally, the reported contribution of the US business, cited at Rs 2,040 crore and 37% for a quarter, underlines why US product launches often receive disproportionate attention in Indian pharma stocks.

Analysis: why this launch is strategically important

The launch adds to Lupin’s US generics portfolio in a therapy area that tends to have ongoing demand due to chronic treatment needs. A large reference market size, cited at Rs 13,437 crore in annual US sales for the 50 mg segment, indicates room for multiple generic participants, but early entry can matter if the field remains narrow. The commentary around a possible six-month exclusivity shared between Lupin and Zydus highlights the value of timing, even as the “at-risk” label points to legal uncertainty. In practical terms, the combination of a large market estimate and constrained early competition is the positive driver cited, while litigation is the main risk flagged in the same set of reports.

What to watch next

The central variables to monitor are any updates in the ongoing litigation and how the competitive set evolves over time. Investors will also watch for signs of how the launch translates into US business performance in subsequent disclosures, given the importance of the geography referenced in quarterly mix data. For now, the confirmed event is Lupin’s US FDA-approved launch of mirabegron extended-release 50 mg in the US, with market commentary highlighting exclusivity potential but also an at-risk backdrop.